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The Trans-Pacific Partnership: Should We “Fear the Fear”?
Comment on “The Trans-Pacific Partnership: Is It Everything We Feared for Health?”
Helen L. Walls, Johanna Hanefeld, Richard D. Smith* 
Abstract
RLabonté et al entitle their paper in this issue of the International Journal of Health Policy and Management “The 
Trans-Pacific Partnership: Is It Everything We Feared for Health?” Tantalisingly, they do not directly answer the 
question they pose, and in this commentary, we suggest that it is the wrong question; we should not ‘fear’ the 
Trans-Pacific Partnership (TPP) at all, rather we should ask how we are to respond. The public health community 
is right to be concerned with the potential implications of trade and investment agreements (TIAs) for health, 
particularly with shifts from multilateral to regional/bilateral agreements including provisions with greater risk to 
public health. But it is critical to understand also the potential health benefits, and especially the mitigating policy 
and governance mechanisms to respond to adverse TIA implications. Given entrenched and divergent sectoral 
worldviews and perspectives between trade and health communities on these issues, achieving the requisite 
understanding will also likely require characterisation of these perspectives and identification of areas of common 
understanding and agreed solutions.
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Franklin D. Roosevelt famously stated that “the only thing we have to fear is fear itself.” It is tempting to suggest that Labonté et al,1 who entitle their paper in this issue 
of the International Journal of Health Policy and Management 
“The Trans-Pacific Partnership: Is It Everything We Feared for 
Health?” might reflect on this. The public health community is 
right to be concerned with the potential implications of trade 
agreements for health. All too frequently, however, the way 
that public health researchers engage with work addressing 
such agreements is taken from a position of hostility, rather 
than a more objective assessment of the possible opportunities 
as well as threats that they may represent; and usually 
uninformed by empirical analysis. Thus, although there is a 
growing body of literature exploring the possible relationships 
between trade and investment agreements (TIAs) and health, 
and suggesting an array of detrimental public health impacts, 
this work has largely been conceptual in nature. There is an 
equally strong body of conceptual literature suggesting the 
positive nature of TIAs for national and global economies, 
with indirect benefits to health; for example.2-5 What is critical 
is to tackle two key areas. First, the challenge of undertaking 
high-quality, holistic empirical research in this complex and 
highly multidisciplinary area to determine the various and 
net impacts of such agreements stemming from direct and 
indirect routes over the short-, medium- and long-term. The 
Labonté et al1 article moves us a step closer in this direction. 
Second, it is critical also to tackle the challenge of developing 
mechanisms that foster positive impact and govern against 
negatives.
This need for evidence and mechanisms is becoming more 
pressing given the rapidly changing nature of the global 
environment of TIAs, with moves from multilateral to 
regional and bilateral agreements, including provisions with 
greater risk to public health. Only a decade ago the focus of 
the public health community in this area was sharply on the 
World Trade Organization (WTO), and agreements such as 
the WTO Agreement on Trade-Related Aspects of Intellectual 
Property Rights (TRIPS), the WTO General Agreement on 
Trade in Services (GATS), and the WTO Technical Barriers to 
Trade (TBT) Agreement.6 Yet even then it was clear that greater 
regional and bilateral development of trading relationships 
and TIAs was becoming more prominent.7-9 Since that time, 
the impact of the investor-state dispute settlement mechanism 
(ISDS) has been clearly seen.10,11 The concerns with these ‘new 
generation’ TIAs – notably the recently signed Trans-Pacific 
Partnership (TPP) between 12 Pacific-Rim countries, and the 
Transatlantic Trade and Investment Partnership (TTIP) under 
negotiation between the United States and the European 
Union (EU) – have been well-documented.12-16 But are they to 
be “feared,” given that fear often paralyses, and a hostile stance 
may contribute to being isolated from negotiation process and 
thus, unable to secure beneficial aspects of TIAs? 
Labonté et al1 do us a great service, as they move beyond the 
conceptual rhetoric in this area, and provide an analysis of 
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specific treaty text – TPP – for possible health impacts using a 
prospective health impact analysis (HIA) methodology. This 
involves the use of a standard protocol for conducting HIAs 
coupled with a health impact review methodology to create 
a summary estimation of the most likely significant impacts 
on health from the cluster of policies making up the TPP. The 
research reviews the final text of the TPP for potential health 
implications of intellectual property rights (IPRs), sanitary 
and phytosanitary provisions (SPS), technical barriers to 
trade (TBT), ISDS and regulatory coherence provisions on a 
range of identified issues, and elucidates a number of serious 
health risks from the TPP. Two of these areas, access to 
medicines and diet-related health, provide us the opportunity 
to illustrate some of these points.
As described by Labonté et al,1 ‘one of the longest standing 
public health concerns with post-WTO TIAs has been their 
potential impact on the price of pharmaceuticals’ (p488-89). 
A key concern about TIAs has been their potential to extend 
intellectual property (IP) provisions in a way that limits 
access to medicines by prolonging or expanding patents and 
curtailing and limiting competition through cheaper generic 
medication. A particular focus has been the concern of TIAs 
extending patent protections for medicines and medical 
procedures beyond those set out in TRIPS, or by eliminating 
the flexibilities and safeguards for health provided by TRIPS, 
to so-called TRIPS-Plus provisions.17 Labonté et al point to 
the TRIPS-Plus provisions in the TTP, as well as to victories 
in safeguarding TRIPS for health. The TRIPS Agreement and 
its provisions for public health are essential to safeguarding 
access to medicines worldwide and the potential impact 
by TIAs have formed a justified focus for research. At the 
same time, we know very little indeed about how and why 
the flexibilities under TRIPS have been implemented or 
not implemented, particularly by low- and middle-income 
countries. There is significant scope for empirical research 
to document and understand the relationship between, and 
politics of invoking, TRIPS for intellectual property, price and 
access to medicines.
TIAs are also increasingly linked to changes in diets, nutrition 
and related health outcomes in countries globally. The 
recognition of this is also growing. For example, in 2015 the 
United Nations’ Standing Committee on Nutrition published a 
report on the need for enhancing coherence between trade 
policy and nutrition action.18 Yet little empirical investigation 
has been undertaken of trade-nutrition relationships, 
catalysing a review of studies in this area that found relatively 
few studies, of a generally low standard (H. Walls, S. Cuevas, 
L. Cornelsen, S. Friel, R. Smith, unpublished data, 2016). This 
reflects the challenge of conducting quality investigation in 
this area, and suggests that novel approaches may be useful 
here. The use of ‘natural experiments’ to investigate these 
relationships is one such example,19,20 although these too are 
not without significant limitations.
Examination of trade-nutrition relationships requires an 
understanding of the various pathways of possible impact 
of TIAs on nutrition, and several frameworks have been 
proposed (H. Walls, S. Cuevas, L. Cornelsen, S. Friel, R. 
Smith, unpublished data, 2016).21-24 In their paper, Labonté 
et al identify areas of particular concern for nutrition in the 
TPP. This includes through the TPP’s TBT and SPS chapters, 
which: promote harmonisation of technical regulations, 
standards, and conformity assessments, arguably to the 
benefit of industry rather than states; increase the scientific 
evidence required for food safety standards; and create new 
avenues for vested interests to participate in regulation-
setting due to administrative demands. The ISDS provision is 
also particularly concerning, as the ‘tobacco exceptionalism’ 
included in the text would not prevent health regulations 
related to other areas of public health, including those 
applied to food products, from being challenged by investors. 
However, it is worth noting that there is a body of literature 
on the positive impacts of global trade on food security and 
dietary measures.25-27
The challenge of undertaking high-quality trade-health 
empirical research is vast, but crucial, given the risks of 
evidence-uninformed policy. Ex-ante studies of potential 
impact, such as that provided by Labonté et al are an 
important advance – they may for example help to inform 
negotiations of possible future problems, and pre-empt 
major harms to the health of populations. But they remain 
predictions, and so ex-post studies of actual impact are also 
needed to substantiate such prediction. If we are to move 
beyond the ‘fear’ then this it is critical to understand more 
fully the impact of potential health risks from TIAs, but also 
potential health benefits. There is also a need for analysis of 
mitigating policy and governance mechanisms to respond to 
adverse TIA implications.28 To achieve this, given entrenched 
sectoral worldviews and divergent understandings of the issue 
between, for example, trade and health communities, will 
also likely require characterisation of these perspectives and 
identification of areas of common understanding and agreed 
solutions.11 Tantalisingly, Labonté et al do not actually answer 
the question they pose: “The Trans-Pacific Partnership: Is It 
Everything We Feared for Health?” We would suggest that 
it is the wrong question; we should not fear the TPP at all, 
rather we should ask how we are to respond. And in this, the 
recommendations and conclusions presented by Labonté et al 
do help to build a way forward, and we heartily endorse their 
implementation.
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